Drug intelligence / Profile preview

Vulvisens

Development stage: Unknown
Lead developer: Initiator Pharma
Modality: Drug Delivery Systems
Administration: Topical

Overview

Vulvisens is a neurodermatological topical ointment developed by Prospera Biotech specifically for feminine intimate care. It is designed to alleviate symptoms such as vulvar irritation, dryness, itching, and burning in the external intimate area. The formulation features neurodermatological ingredients that target nerve endings to reduce uncomfortable sensations, complemented by a blend of botanical components: avocado oil for moisturizing, prebiotics to support the natural skin microbiota, rosehip extract for its regenerative properties, and calendula extract for anti-inflammatory effects. Marketed as a cosmetic product rather than a pharmaceutical drug, it is suitable for individuals from three years of age and has been tested under gynecological and pediatric supervision.

Brand names: Vulvisens

Beyond the preview

Go deeper on Vulvisens.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vulvisens.

Explore the full profile